Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included payment of $440 million at closing, with an additional $25 million tied to 2026 revenue targets. Read More
Automata Technologies Ltd. raised $45 million in a series C funding round that included a strategic investment partnership with Danaher Corp. The funds will be used to support the scaling of customer deployments, the building of the next generation of Automata’s data and closed-loop experimentation software platform and the expansion of its global operations. Read More
A new draft guidance for organ procurement organizations doing business in the U.S. would seem to tackle some pressing issues with organ donation, such as the conditions in which a problem qualifies as an adverse event. Perhaps of greater interest to companies in the organ container business is that the Centers for Medicare & Medicaid Services is intent on increasing the availability of organ donations to deal with an insatiable demand for donated organs. Read More
Total med-tech financing activity surged in the fourth quarter of 2025, with $16.21 billion raised across all financing categories, more than double the $5.78 billion recorded in Q3 and the strongest quarterly total of the year. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting.
This transition reflects how innovation across the life sciences is increasingly interconnected. By featuring med-tech coverage within BioWorld, readers gain a more complete perspective of key developments in medical technologies alongside therapeutics all in one place.
The final edition of BioWorld MedTech will publish on Jan. 30, 2026, introducing a more streamlined and comprehensive experience for readers starting on Monday, Feb. 2, 2026.
All existing BioWorld MedTech subscribers will be automatically transitioned to BioWorld Premium, ensuring continued access to med-tech coverage as part of a broader view of research, clinical development and commercialization.
As BioWorld continues its mission to cut through the noise of the life sciences industry with accuracy, clarity and context, this integration ensures readers are well-positioned to track the connections shaping innovation across the global life sciences ecosystem.
Thank you for being part of the BioWorld MedTech community. We invite you to continue following coverage within BioWorld.
Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Koru Medical, Siemens Healthineers. Read More
